Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Gattinoni Website

Luca Gattinoni, M.D.

Selected Publications

1)  Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, Roychoudhuri R, Palmer DC, Muranski P, Karoly ED, Mohney RP, Klebanoff CA, Lal A, Finkel T, Restifo NP, Gattinoni L.
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function.
J. Clin. Invest. 123: 4479-4488, 2013.
2)  Dudda JC, Salaun B, Ji Y, Palmer DC, Monnot GC, Merck E, Boudousquie C, Utzschneider DT, Escobar TM, Perret R, Muljo SA, Hebeisen M, Rufer N, Zehn D, Donda A, Restifo NP, Held W, Gattinoni L, Romero P.
MicroRNA-155 Is Required for Effector CD8(+) T Cell Responses to Virus Infection and Cancer.
Immunity. 38: 742-53, 2013.
3)  Ji Y, Pos Z, Rao M, Klebanoff CA, Yu Z, Sukumar M, Reger RN, Palmer DC, Borman ZA, Muranski P, Wang E, Schrump DS, Marincola FM, Restifo NP, Gattinoni L.
Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8(+) T cells.
Nat. Immunol. 12: 1230-7, 2011.
4)  Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, Wang E, Douek DC, Price DA, June CH, Marincola FM, Roederer M, Restifo NP.
A human memory T cell subset with stem cell-like properties.
Nat. Med. 17: 1290-7, 2011.
5)  Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, Wrzesinski C, Boni A, Cassard L, Garvin LM, Paulos CM, Muranski P, Restifo NP.
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells.
Nat. Med. 15: 808-13, 2009.
6)  Restifo NP, Gattinoni L.
Lineage relationship of effector and memory T cells.
Curr. Opin. Immunol. 25: 556-63, 2013.
7)  Thaventhiran JE, Fearon DT, Gattinoni L.
Transcriptional regulation of effector and memory CD8(+) T cell fates.
Curr. Opin. Immunol. 25: 321-8, 2013.
8)  Gattinoni L, Klebanoff CA, Restifo NP.
Paths to stemness: building the ultimate antitumour T cell.
Nat. Rev. Cancer. 12: 671-84, 2012.
9)  Roychoudhuri R, Hirahara K, Mousavi K, Clever D, Klebanoff CA, Bonelli M, Sciumè G, Zare H, Vahedi G, Dema B, Yu Z, Liu H, Takahashi H, Rao M, Muranski P, Crompton JG, Punkosdy G, Bedognetti D, Wang E, Hoffmann V, Rivera J, Marincola FM, Nakamura A, Sartorelli V, Kanno Y, Gattinoni L, Muto A, Igarashi K, O'Shea JJ, Restifo NP.
BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis.
Nature. 498: 506-10, 2013.
10)  Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA, Restifo NP.
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.
J. Clin. Invest. 115: 1616-26, 2005.
11)  Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, Burns WR, Miermont AM, Teper Y, Rudloff U, Restifo NP, Feldman SA, Rosenberg SA, Morgan RA.
A novel chimeric antigen receptor against PSCA mediates tumor destruction in a humanized mouse model of pancreatic cancer.
Hum. Gene Ther. [Epub ahead of print], 2014.
12)  Ji Y, Abrams N, Zhu W, Salinas E, Yu Z, Palmer DC, Jailwala P, Franco Z, Roychoudhuri R, Stahlberg E, Gattinoni L, Restifo NP.
Identification of the Genomic Insertion Site of Pmel-1 TCR a and ß Transgenes by Next-Generation Sequencing.
PLoS ONE. 9: e96650, 2014.
13)  Sukumar M, Gattinoni L.
The short and sweet of T-cell therapy: Restraining glycolysis enhances the formation of immunological memory and antitumor immune responses.
Oncoimmunology. 3: e27573, 2014.
14)  Lugli E, Gattinoni L, Roberto A, Mavilio D, Price DA, Restifo NP, Roederer M.
Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells.
Nat Protoc. 8: 33-42, 2013.
15)  Gattinoni L, Restifo NP.
Moving T memory stem cells to the clinic.
Blood. 121: 567-8, 2013.
16)  Klebanoff CA, Spencer SP, Torabi-Parizi P, Grainger JR, Roychoudhuri R, Ji Y, Sukumar M, Muranski P, Scott CD, Hall JA, Ferreyra GA, Leonardi AJ, Borman ZA, Wang J, Palmer DC, Wilhelm C, Cai R, Sun J, Napoli JL, Danner RL, Gattinoni L, Belkaid Y, Restifo NP.
Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cells.
J. Exp. Med. 210: 1961-76, 2013.
17)  Lugli E, Dominguez MH, Gattinoni L, Chattopadhyay PK, Bolton DL, Song K, Klatt NR, Brenchley JM, Vaccari M, Gostick E, Price DA, Waldmann TA, Restifo NP, Franchini G, Roederer M.
Superior T memory stem cell persistence supports long-lived T cell memory.
J. Clin. Invest. 123: 594-9, 2013.
18)  Yang S, Ji Y, Gattinoni L, Zhang L, Yu Z, Restifo NP, Rosenberg SA, Morgan RA.
Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails.
Cancer Immunol. Immunother. 2012.
19)  Stroncek DF, Berger C, Cheever MA, Childs RW, Dudley ME, Flynn P, Gattinoni L, Heath JR, Kalos M, Marincola FM, Miller JS, Mostoslavsky G, Powell DJ, Rao M, Restifo NP, Rosenberg SA, O'Shea J, Melief CJ.
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer.
J Transl Med. 10: 48, 2012.
20)  Klebanoff CA, Gattinoni L, Restifo NP.
Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?.
J. Immunother. 35: 651-60, 2012.
21)  Klebanoff CA, Gattinoni L.
Stubborn Tregs limit T-cell therapy.
Blood. 120: 2352-4, 2012.
22)  Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, Borman ZA, Kerkar SP, Scott CD, Finkelstein SE, Rosenberg SA, Restifo NP.
Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.
Clin. Cancer Res. 17: 5343-52, 2011.
23)  Kerkar SP, Sanchez-Perez L, Yang S, Borman ZA, Muranski P, Ji Y, Chinnasamy D, Kaiser AD, Hinrichs CS, Klebanoff CA, Scott CD, Gattinoni L, Morgan RA, Rosenberg SA, Restifo NP.
Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.
J. Immunother. 34: 343-52, 2011.
24)  Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns WR, Huang J, Klebanoff CA, Johnson LA, Kerkar SP, Yang S, Muranski P, Palmer DC, Scott CD, Morgan RA, Robbins PF, Rosenberg SA, Restifo NP.
Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.
Blood. 117: 808-14, 2011.
25)  Yang S, Gattinoni L, Luca G, Liu F, Ji Y, Yu Z, Restifo NP, Rosenberg SA, Morgan RA.
In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells.
Cancer Immunol. Immunother. 60: 739-49, 2011.
26)  Hu G, Schones DE, Cui K, Ybarra R, Northrup D, Tang Q, Gattinoni L, Restifo NP, Huang S, Zhao K.
Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1.
Genome Res. 21: 1650-8, 2011.
27)  Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, Sukumar M, Reger RN, Yu Z, Kern SJ, Roychoudhuri R, Ferreyra GA, Shen W, Durum SK, Feigenbaum L, Palmer DC, Antony PA, Chan CC, Laurence A, Danner RL, Gattinoni L, Restifo NP.
Th17 Cells Are Long Lived and Retain a Stem Cell-like Molecular Signature.
Immunity. 35: 972-85, 2011.
28)  Flatz L, Hegazy AN, Bergthaler A, Verschoor A, Claus C, Fernandez M, Gattinoni L, Johnson S, Kreppel F, Kochanek S, Broek M, Radbruch A, Lévy F, Lambert PH, Siegrist CA, Restifo NP, Löhning M, Ochsenbein AF, Nabel GJ, Pinschewer DD.
Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8(+) T cell immunity.
Nat. Med. 16: 339-45, 2010.
29)  Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, Yu Z, Rosenberg SA, Restifo NP.
Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.
J. Immunother. 33: 1-7, 2010.
30)  Kerkar SP, Muranski P, Kaiser A, Boni A, Sanchez-Perez L, Yu Z, Palmer DC, Reger RN, Borman ZA, Zhang L, Morgan RA, Gattinoni L, Rosenberg SA, Trinchieri G, Restifo NP.
Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.
Cancer Res. 70: 6725-34, 2010.
31)  Gattinoni L, Ji Y, Restifo NP.
Wnt/{beta}-Catenin Signaling in T-Cell Immunity and Cancer Immunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research. 2010.
32)  Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern SJ, Logun C, Palmer DC, Ji Y, Reger RN, Leonard WJ, Danner RL, Rosenberg SA, Restifo NP.
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.
Proc. Natl. Acad. Sci. U.S.A. 106: 17469-74, 2009.
33)  Gattinoni L, Klebanoff CA, Restifo NP.
Pharmacologic induction of CD8+ T cell memory: better living through chemistry.
Sci Transl Med. 1: 11ps12, 2009.
34)  Klebanoff CA, Yu Z, Hwang LN, Palmer DC, Gattinoni L, Restifo NP.
Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.
Blood. 114: 1776-83, 2009.
35)  Boni A, Muranski P, Cassard L, Wrzesinski C, Paulos CM, Palmer DC, Gattinoni L, Hinrichs CS, Chan CC, Rosenberg SA, Restifo NP.
Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.
Blood. 112: 4746-54, 2008.
36)  Palmer DC, Chan CC, Gattinoni L, Wrzesinski C, Paulos CM, Hinrichs CS, Powell DJ, Klebanoff CA, Finkelstein SE, Fariss RN, Yu Z, Nussenblatt RB, Rosenberg SA, Restifo NP.
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity.
Proc. Natl. Acad. Sci. U.S.A. 105: 8061-6, 2008.
37)  Hinrichs CS, Spolski R, Paulos CM, Gattinoni L, Kerstann KW, Palmer DC, Klebanoff CA, Rosenberg SA, Leonard WJ, Restifo NP.
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.
Blood. 111: 5326-33, 2008.
38)  Abad JD, Wrzensinski C, Overwijk W, De Witte MA, Jorritsma A, Hsu C, Gattinoni L, Cohen CJ, Paulos CM, Palmer DC, Haanen JB, Schumacher TN, Rosenberg SA, Restifo NP, Morgan RA.
T-cell receptor gene therapy of established tumors in a murine melanoma model.
J. Immunother. 31: 1-6, 2008.
39)  Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann KW, Feigenbaum L, Chan CC, Restifo NP.
Tumor-specific Th17-polarized cells eradicate large established melanoma.
Blood. 112: 362-73, 2008.
40)  Lionello I, Mangia P, Gattinoni L, Pende D, Cippone A, Sensi M, Rigatti P, Traversari C.
CD8(+) T lymphocytes isolated from renal cancer patients recognize tumour cells through an HLA- and TCR/CD3-independent pathway.
Cancer Immunol. Immunother. 56: 1065-76, 2007.
41)  Zhao Y, Parkhurst MR, Zheng Z, Cohen CJ, Riley JP, Gattinoni L, Restifo NP, Rosenberg SA, Morgan RA.
Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling.
Cancer Res. 67: 2425-9, 2007.
42)  Wrzesinski C, Paulos CM, Gattinoni L, Palmer DC, Kaiser A, Yu Z, Rosenberg SA, Restifo NP.
Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells.
J. Clin. Invest. 117: 492-501, 2007.
43)  Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, Palmer DC, Boni A, Muranski P, Yu Z, Gattinoni L, Antony PA, Rosenberg SA, Restifo NP.
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling.
J. Clin. Invest. 117: 2197-204, 2007.
44)  Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, Muranski P, Sanchez-Perez L, Palmer DC, Yu Z, Antony PA, Gattinoni L, Rosenberg SA, Restifo NP.
Toll-like receptors in tumor immunotherapy.
Clin. Cancer Res. 13: 5280-9, 2007.
45)  Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP.
Adoptive immunotherapy for cancer: building on success.
Nat. Rev. Immunol. 6: 383-93, 2006.
46)  Klebanoff CA, Gattinoni L, Restifo NP.
CD8+ T-cell memory in tumor immunology and immunotherapy.
Immunol. Rev. 211: 214-24, 2006.
47)  Gattinoni L, Ranganathan A, Surman DR, Palmer DC, Antony PA, Theoret MR, Heimann DM, Rosenberg SA, Restifo NP.
CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent.
Blood. 108: 3818-23, 2006.
48)  Zhao Y, Zheng Z, Cohen CJ, Gattinoni L, Palmer DC, Restifo NP, Rosenberg SA, Morgan RA.
High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation.
Mol. Ther. 13: 151-9, 2006.
49)  Hinrichs CS, Gattinoni L, Restifo NP.
Programming CD8+ T cells for effective immunotherapy.
Curr. Opin. Immunol. 18: 363-70, 2006.
50)  Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA, Waldmann TA, Restifo NP.
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.
Proc. Natl. Acad. Sci. U.S.A. 102: 9571-6, 2005.
51)  Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, Surh CD, Rosenberg SA, Restifo NP.
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.
J. Exp. Med. 202: 907-12, 2005.
52)  Bajetta E, Procopio G, Celio L, Gattinoni L, Della Torre S, Mariani L, Catena L, Ricotta R, Longarini R, Zilembo N, Buzzoni R.
Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women.
J. Clin. Oncol. 23: 2155-61, 2005.
53)  Finkelstein SE, Heimann DM, Klebanoff CA, Antony PA, Gattinoni L, Hinrichs CS, Hwang LN, Palmer DC, Spiess PJ, Surman DR, Wrzesiniski C, Yu Z, Rosenberg SA, Restifo NP.
Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer.
J. Leukoc. Biol. 76: 333-7, 2004.
54)  Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC, Tagaya Y, Rosenberg SA, Waldmann TA, Restifo NP.
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.
Proc. Natl. Acad. Sci. U.S.A. 101: 1969-74, 2004.
55)  Melloni G, Ferreri AJ, Russo V, Gattinoni L, Arrigoni G, Ceresoli GL, Zannini P, Traversari C.
Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients.
Oncol. Rep. 12: 145-51, 2004.
56)  Gattinoni L, Alù M, Ferrari L, Nova P, Del Vecchio M, Procopio G, Laudani A, Agostara B, Bajetta E.
Renal cancer treatment: a review of the literature.
Tumori. 89: 476-84, 2004.
57)  Del Vecchio M, Gattinoni L, Lozza L, Bajetta E.
Unusual aspects of melanoma. Case 2. Regionally advanced nasal cavity melanoma.
J. Clin. Oncol. 22: 745-6, 2004.
58)  Palmer DC, Balasubramaniam S, Hanada K, Wrzesinski C, Yu Z, Farid S, Theoret MR, Hwang LN, Klebanoff CA, Gattinoni L, Goldstein AL, Yang JC, Restifo NP.
Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.
J. Immunol. 173: 7209-16, 2004.
59)  Ferrari L, Bajetta E, Martinetti A, Celio L, Longarini R, La Torre I, Buzzoni R, Gattinoni L, Seregni E, Bombardieri E.
Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?.
Int. J. Oncol. 22: 1081-9, 2003.
60)  Ferrari L, Martinetti A, Zilembo N, Pozzi P, Buzzoni R, La Torre I, Gattinoni L, Catena L, Vitali M, Celio L, Seregni E, Bombardieri E, Bajetta E.
Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients.
J. Steroid Biochem. Mol. Biol. 80: 411-8, 2002.
61)  Fleischhauer K, Gattinoni L, Lietti G, Zino E, Bordignon C, Traversari C.
Identification of tumor antigen-specific cytotoxic T lymphocytes cross-recognizing allogeneic major histocompatibility class I molecules.
Tissue Antigens. 56: 19-29, 2000.
62)  Fleischhauer K, Gattinoni L, Dalerba P, Lauvau G, Zanaria E, Dabovic B, van Endert PM, Bordignon C, Traversari C.
The DAM gene family encodes a new group of tumor-specific antigens recognized by human leukocyte antigen A2-restricted cytotoxic T lymphocytes.
Cancer Res. 58: 2969-72, 1998.
Click Here to View Collapsed Bibliography.

This page was last updated on 6/12/2014.